The one human trial that will measure tolerability directly has not started reporting it is only recruiting (planned 2026), studies a topical gel on small standardized wounds , and lists safety as a secondary, not primary, outcome (NCT07437586)
This powerful antioxidant may help inhibit melanin production, leading to a more even and radiant complexion
In real biology, healing is not a single lever you pull
Functional Foods in Health and Disease, 14 (3), 184-206
doi: 10.3390/biomedicines11071840
Community protocols on TRT describe: BPC-157: 250-500 mcg subcutaneous, 1-2x daily (near the injury site when possible) TB-500: 2-5 mg subcutaneous, 2x per week (loading), then 2 mg weekly (maintenance) Stacking both for 4-8 weeks for injury recovery No cycling described used as needed during recovery periods For the detailed breakdown, see our BPC-157 dosing guide, TB-500 dosing guide, and the BPC-157 vs TB-500 comparison